Antigen News and Research

RSS

Cancers successfully treated by targeting the viruses that cause them

Researchers at the Albert Einstein College of Medicine of Yeshiva University have shown for the first time that cancers can be successfully treated by targeting the viruses that cause them.

31 Oct 2007

Researchers show evidence of 'memory' in cells and molecules

Research to be reported October 29 in the journal Proceedings of the National Academy of Sciences (PNAS) provides evidence that some molecular interactions on cell surfaces may have a "memory" that affects their future interactions.

29 Oct 2007

Nventa Biopharmaceuticals receives new U.S. patent

Nventa Biopharmaceuticals Corporation has announced that the U.S. Patent and Trademark Office has issued Patent Number 7,262,014 to Nventa covering compositions and methods for inducing or enhancing immune responses to a human papillomavirus (HPV) antigen with or without the use of an adjuvant.

29 Oct 2007

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007

Influenza vaccine production capacity on the rise

Recent scientific advances and increased vaccine manufacturing capacity have prompted experts to increase their projections of how many pandemic influenza vaccine courses can be made available in the coming years.

24 Oct 2007

In the event of a bird flu pandemic more vaccine will be ready

The World Health Organization (WHO) has revised it's estimate of how much bird flu vaccine could be available were a pandemic scenario to unfold.

24 Oct 2007

Ubiquitin builds up an immune response

Ubiquitin is a small protein, which can be attached to other cellular proteins, a process known as ubiquitination.

22 Oct 2007

Abbott creates one molecule with two antibody functions

Abbott has reported that its scientists are the first to discover a proprietary technology that combines the function and specificity of two or more monoclonal antibodies (mAbs) into one molecular entity that demonstrates drug-like properties and manufacturing feasibility.

19 Oct 2007

Discovery of new antibody that helps detect type 1 diabetes

Researchers at the Barbara Davis Center for Childhood Diabetes and University of Colorado at Denver and Health Sciences Center's School of Medicine have discovered a fourth antibody in human blood which will help more accurately predict who is predisposed to type 1 diabetes.

17 Oct 2007

A tumor marker Ca 19-9 in diabetics can lead to misdiagnosis of pancreatic cancer

Diabetes is increasing all over the world along with the increase of obesity and associated diseases and is a well-known risk factor for pancreatic cancer. The incidence of pancreatic cancer is also increasing and has one of the lowest survival rates of all cancers.

16 Oct 2007

Discovery of way to match pathogens to their antibodies

The search for a vaccination against HIV has been in progress since 1984, with very little success.

15 Oct 2007

AMDL submits data to FDA for clearance to market its diagnostic test to monitor colorectal cancer patients

AMDL, Inc., developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has filed with the U.S. Food & Drug Administration (FDA) for clearance to market its unique, proprietary DR-70 (FDP) ELISA tumor marker test for use as an aid in monitoring patients previously diagnosed with colorectal cancer. AMDL used the guidance provided at the meeting they had with the FDA on January 25, 2007.

15 Oct 2007

Bacteria reveal targets of immune responses quick and direct identification of antigens

The Epstein-Barr virus (EBV) is a widespread herpes virus that infects more than 90 per cent of the worldwide human population.

10 Oct 2007

PSA velocity's value as a prostate cancer screening tool

Some studies have suggested that the rate of change of prostate-specific antigen (PSA) levels may correspond with prostate cancer survival.

10 Oct 2007

African-American men have a slightly higher risk of PSA recurrence

African-American men are more likely to have their prostate cancer return after treatment, but their disease is no more aggressive when it does recur than that of their white counterparts, according to a study led by Duke Prostate Center researchers.

10 Oct 2007

$Accentia announces investigational new drug application for Revimmune for refractory MS$

Accentia announces investigational new drug application for Revimmune for refractory MS

Accentia Biopharmaceuticals has announced that it met with the Food and Drug Administration (FDA) on September 26, 2007 for a scheduled pre-Investigational New Drug (pre-IND) meeting on Revimmune.

10 Oct 2007

Dual action anthrax vaccine-antitoxin combination developed

The immune response generated in rats by the new agent protects against lethal toxin exposure after only one injection, and is faster and stronger than any currently available vaccine.

8 Oct 2007

Completion of first clinical trial of Apatone for cancer treatment

In a significant advancement in the ongoing battle against cancer, a group of researchers from Summa Health System, IC-MedTech and other institutions have completed the first ever FDA-approved human clinical trial of Apatone®.

8 Oct 2007

Improvements in cancer survival in Northern Ireland

There have been improvements in cancer survival in Northern Ireland between 1993 and 2004, according to a new report from the Northern Ireland Cancer Registry (NICR), launched at Queen’s today.

4 Oct 2007

Specific immune deficiency pinpointed as likely cause of ulcerative colitis

In a series of mouse experiments, researchers at the Harvard School of Public Health (HSPH) have pinpointed a specific immune deficiency as the likely fundamental cause of ulcerative colitis, a chronic, sometimes severe inflammatory disease of the colon or large intestine that afflicts half a million Americans.

4 Oct 2007